Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of multiple ianalumab doses administered subcutaneously in patients with moderate to severe primary Sjogren's Syndrome

Next Previous
X
Search
Trial Profile

A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of multiple ianalumab doses administered subcutaneously in patients with moderate to severe primary Sjogren's Syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ianalumab (Primary)
  • Indications Sjogren's syndrome
  • Focus Therapeutic Use
  • Sponsors Novartis; Novartis Pharma KK; Novartis Pharmaceuticals

    • Most Recent Events

    • 15 Jun 2024 Results (n=190) characterizing the biomarkers associated with disease activity and clinical dose response in improving the whole salivary flow, presented at the 25th Annual Congress of the European League Against Rheumatism
    • 15 Nov 2023 Results assessing dose dependent modulation of a B cell protein signature by Ianalumab in patients with Sjogren's-syndrome presented at the ACR Convergence 2023
    • 03 Dec 2021 Results published in the Lancet.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top